Reactive microglia are positive for HLA-DR in the: Substantia nigra of Parkinson’s and Alzheimer’s disease brains

Neurology

Volumn 38, Issue 8, 1988, Pages 1285-1291

  McGeer, P L ^a   Itagaki, S ^a   Boyes, B E ^a   McGeer, E G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE ACETYLTRANSFERASE; HLA DR ANTIGEN;

ADULT; AGED; ALZHEIMER DISEASE; AUTOPSY; CLINICAL ARTICLE; FEMALE; HIPPOCAMPUS; HISTOCHEMISTRY; HUMAN; MALE; MICROGLIA; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN CHEMISTRY; DEMENTIA; FEMALE; HLA-D ANTIGENS; HLA-DR ANTIGENS; HUMAN; MALE; MELANINS; MIDDLE AGE; NEUROGLIA; PARKINSON DISEASE; SUBSTANTIA NIGRA; SUPPORT, NON-U.S. GOV'T;

EID: 0023789193     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.38.8.1285     Document Type: Article

References (27)

1. Stites DP, Stobo JD, Wells JV. Basic and clinical immunology, 6th ed. Norwalk, CT Appleton & Lange, 1987.
2. Penfield W. Microglia and the process of phagocytosis in gliomae. Am J Pathol 1925;1:77–89.
3. Ling EA. The origin and nature of microglia. Adv Cell Neurobiol 1981;2:33–82.
4. Schelper RL, Adrian EK. Monocytes become macrophagee; they do not become microglia: a light and electron microscopic auto-radiographic study using 125-iododeoxyuridine. J Neuropathol Exp Neurol 1986;45:1–19.
5. Perry RH, Tomlinson BE, Candy JM, et al. Cortical cholinergic deficits in mentally impaired parkinsonian patienta. Lancet 1983;2:789–790.
6. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987;79:195–200.
7. McGeer PL, McGeer EG, Itagaki S, Mizukawa K. Anatomy and pathology of the basal ganglia. Can J Neurol Sci 1987;14:363–372.
8. McGeer EG, McGeer PL, Kamo H, Tago H, Harmp R. Cortical metabolism, acetylcholinesterase staining and pathological changes in Alzheimer’s dieease. Can J Neurol Sci 1986;13:511–516.
9. McGeer EG, Norman M, Boyes BE, O’Kuaky J, Suzuki J, McGeer PL. Acetylcholine and aromatic mine systems in postmortem brain of an infant with Down’s syndrome. Exp Neurol 1985;87:557–570.
10. 18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects. Life Sci 1986;39:2243–2252.
11. Tago H, McGeer PL, Bruce G, Hersh LB. Distribution of choline acetyltransferase containing neurons of the hypothalamus. Brain Res 1987;415:49–62.
12. Hakim AM, Mathieson G. Dementia in Parkinson’s disease: a neuropathologic study. Neurology 1979;29:1209–1214.
13. Itagaki S, McGeer PL, McGeer EG. HLA-DR reactive microglia in Parkinson’s disease. J Neuroimmunol 1987;16:81.
14. McGeer PL, Itagaki S, Tago H, McGeer EG. Expreesion of HLA-DR and interleukin-2 receptors on reactive microglia in senile dementia of the Alzheimer’s type. J Neuroimmunol 1987;16:122.
15. Adolfwn R, Gottfriee CG, Roos BE, Winblad B. Post-mortem determination of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature. J Neural Transm 1979;45.81–105.
16. Cumminga JL. Subcortical dementia: neuropsychology, neuropsy-chiatry, and pathophyeiology. Br J Psychiatry 1986;149:682–697.
17. Gaspar F, Gray D. Dementia in idiopathic Parkinson’s disease. Acta Neuropathol (Berl) 1984;64:43–52.
18. Boller F, Mizutani T, Roeesmann U, Gambetti P. Parkinson disease, dementia and Alzheimer disease: clinicopathological correlations. Ann Neurol 1980;7:329–335.
19. Ditter SM, Mirra SS. Neuropathologic and clinical features of Parkinson’s disease in Alzheimer’s disease patients. Neurology 1987;37:754–760.
20. Giménez-Roldán S, Mateo D, Escalona-Zapata J. Familial Alzheimer’s disease preaenting as levodopa-responsive parkinsonism. Adv Neurol 1986;45:431–436.
21. Brown RG, Mareden CD. How common is dementia in Parkinson’s disease? Lancet 1984;2:1262–1265.
22. Lieberman A, Dziatolowski M, Kupersmith M, et al. Dementia in Parkinson dieeaee. Ann Neurol 1979;6:355–359.
23. Heilig CW, Knopman DS, Mastri AR, Frey W II. Dementia without Alzheimer pathology. Neurology 1985;35:762–765.
24. Chui HC, Mortimer JA, Slager U, Zarow C, Bondareff W, Webster DD. Pathologic correlates of dementia in Parkinson’s disease. Arch Neurol 1986;43:991–995.
25. Woodroofe MN, Bellamy AS, Feldmann M, Davison AN, Cuzner ML. Immunocytuchemical characterization of the immune reaction in the central nervous syetem in multiple sclerosis. J Neurol Sci 1986;74:135–152.
26. Lampson LA, Hickey WF. Monoclonal antibody analysis of MHC expression in human brain biopsies: tiasue ranging from “histo-logically normal” to that showing different levels of glial tumor involvement. J Immunol 1986;136:4054–4062.
27. Traugott U. Multiple sclerosis: relevance of class I and claas I1 MHC-expreeaing cells to lesion development. J Neuroimmunol 1987;16:283–302.